Montral (Montelukast + Levocetirizine)

• Composition :
  Montelukast 10 mg + Levocetirizine 5 mg Tablets
• Indications :
  For the treatment of allergic rhinitis
• Pharmacodynamics :
  Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptors which play a main role in pathophysiology of allergic rhinitis. Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.
• Dosage and administration :
  Adults (>15 years): 1 tablet once daily
• Contraindications :
  Is contraindicated in patients with known hypersensitivity to montelukast sodium, levocetirizine or cetirizine or to any other component of this product
• Precautions and warnings :
  Patients on therapy with Montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis. Patients should avoid engaging in hazardous occupation requiring complete mental alertness such as driving or operating machinery when taking levocetirizine.
• Use in pregnancy, lactation & pediatrics :
  There are no adequate and well controlled studies of either montelukast or levocetirizine in pregnant women, this combination is not recommended during lactation, montelukast : The safety and effectiveness in pediatric patients below the age of 12 months with asthma and 6 months with allergic rhinitis have not been established. Levocetirizine: . In children 2 to 6 years of age the recommended dose of 2.5 mg once daily should not be exceeded.
• Drug interactions :
  Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma.
• Adverse reactions :
  Most common adverse effects are upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis
• Therapy Area :
  Anti-Allergics